{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:50:32Z","timestamp":1787878232661,"version":"build-2784847793"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      We assessed the efficacy and safety of mirabegron, a \u03b2\n                      <jats:sub>3<\/jats:sub>\n                      -adrenoceptor agonist, in older adults (\u2265\u200980\u00a0years old) with overactive bladder (OAB).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>OAB patients aged\u2009\u2265\u200980\u00a0years were enrolled in this prospective, single-arm observational study. OAB was diagnosed based on the OAB symptom score (OABSS); i.e., a total score of\u2009\u2265\u20093 points and an urgency score of\u2009\u2265\u20092 points. Patients who received 50\u00a0mg mirabegron once daily were evaluated at the baseline and at 4, 8, and 12\u00a0weeks. The changes from the baseline in the OABSS, International Prostate Symptom Score (IPSS), OAB questionnaire (OAB-q) score, and Vulnerable Elders Survey (VES-13) score were determined. Adverse events, laboratory tests, 12-lead electrocardiography, the QT interval according to Fridericia\u2019s formula (QTcF), uroflowmetry, the post-void residual urine volume (PVR), and the Mini-Mental State Examination (MMSE) score were used to assess safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-three patients (median age: 84\u00a0years, range: 80\u201396\u00a0years) were examined. They had high rates of comorbidities and polypharmacy. Mirabegron significantly improved in total score of the OABSS, including urgency and urge incontinence. The total IPSS, IPSS quality-of-life (QOL) index, and OAB-q scores also significantly improved. Mirabegron improved in the VES-13 score. There were no significant changes in laboratory test values, uroflowmetry findings, PVR, the QTcF, or MMSE score. Two patients (4.7%) withdrew from the study after experiencing adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mirabegron was well tolerated and significantly improved in OAB symptoms, and QOL in older patients.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      The present clinical study was approved by University of Yamanashi Institutional Review Board prior to study initiation (ID1447) and was retrospectively registered with the UMIN Clinical Trials Registry (UMIN-CTR), Japan (UMIN000045996) on Nov 6, 2021.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-022-00989-7","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T15:03:29Z","timestamp":1647875009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Mirabegron for overactive bladder in frail patients 80\u00a0years or over (HOKUTO study)"],"prefix":"10.1186","volume":"22","author":[{"given":"Hiroshi","family":"Nakagomi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0408-3678","authenticated-orcid":false,"given":"Takahiko","family":"Mitsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Ihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"989_CR1","first-page":"1183","volume":"27","author":"H Yamagami","year":"2014","unstructured":"Yamagami H, Imura M, Hiro S. The demographics and treatment circumstances of patients receiving OAB treatment medication. Jpn J Urol Surg. 2014;27:1183\u201390.","journal-title":"Jpn J Urol Surg"},{"key":"989_CR2","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/wvn.12508","volume":"18","author":"W Chu","year":"2021","unstructured":"Chu W, Chang SF, Ho HY. Adverse health effects of frailty: systematic review and meta-analysis of middle-aged and older adults with implications for evidence-based practice. Worldviews Evid Based Nurs. 2021;18:282\u20139.","journal-title":"Worldviews Evid Based Nurs"},{"issue":"8","key":"989_CR3","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1002\/nau.24148","volume":"38","author":"K Omae","year":"2019","unstructured":"Omae K, et al. Gait speed and overactive bladder in the healthy community-dwelling super elderly: the Sukagawa study. Neurourol Urodyn. 2019;38(8):2324\u201332.","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"989_CR4","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/luts.12292","volume":"12","author":"O Soma","year":"2020","unstructured":"Soma O, et al. Relationship between frailty and lower urinary tract symptoms among community-dwelling adults. Low Urin Tract Symptoms. 2020;12(2):128\u201336.","journal-title":"Low Urin Tract Symptoms"},{"issue":"1","key":"989_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.urology.2010.06.044","volume":"77","author":"Y Homma","year":"2011","unstructured":"Homma Y, et al. Assessment of overactive bladder symptoms: comparison of 3-day bladder diary and the overactive bladder symptoms score. Urology. 2011;77(1):60\u20134.","journal-title":"Urology"},{"issue":"14","key":"989_CR6","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1200\/JCO.2006.10.2954","volume":"25","author":"MB Rodin","year":"2007","unstructured":"Rodin MB, Mohile SG. A practical approach to geriatric assessment in oncology. J Clin Oncol. 2007;25(14):1936\u201344.","journal-title":"J Clin Oncol"},{"key":"989_CR7","first-page":"168","volume":"18","author":"M Sugishita","year":"2016","unstructured":"Sugishita M, Hemmi I, Takeuchi T. Reexamination of the validity and reliability of the Japanese version of the Mini-Mental State Examination (MMSE-J). Jpn J Cogn Neurosci. 2016;18:168\u201383.","journal-title":"Jpn J Cogn Neurosci"},{"issue":"5","key":"989_CR8","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.urology.2010.08.039","volume":"77","author":"KS Coyne","year":"2011","unstructured":"Coyne KS, et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081\u20137.","journal-title":"Urology"},{"issue":"6","key":"989_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327\u201336.","journal-title":"World J Urol"},{"issue":"1","key":"989_CR10","first-page":"28","volume":"18","author":"Y Soliman","year":"2016","unstructured":"Soliman Y, Meyer R, Baum N. Falls in the elderly secondary to urinary symptoms. Rev Urol. 2016;18(1):28\u201332.","journal-title":"Rev Urol"},{"issue":"12","key":"989_CR11","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1080\/03007995.2016.1226167","volume":"32","author":"ML Ganz","year":"2016","unstructured":"Ganz ML, et al. Real-world characteristics of elderly patients with overactive bladder in the United States. Curr Med Res Opin. 2016;32(12):1997\u20132005.","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"989_CR12","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s12325-018-0796-8","volume":"35","author":"SM Szabo","year":"2018","unstructured":"Szabo SM, et al. The association between overactive bladder and falls and fractures: a systematic review. Adv Ther. 2018;35(11):1831\u201341.","journal-title":"Adv Ther"},{"issue":"10","key":"989_CR13","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/iju.13758","volume":"25","author":"M Yoshida","year":"2018","unstructured":"Yoshida M, et al. Anticholinergic burden in the Japanese elderly population: use of antimuscarinic medications for overactive bladder patients. Int J Urol. 2018;25(10):855\u201362.","journal-title":"Int J Urol"},{"issue":"3","key":"989_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2165\/11586580-000000000-00000","volume":"28","author":"MP Fortin","year":"2011","unstructured":"Fortin MP, et al. Effects of anticholinergic drugs on verbal episodic memory function in the elderly: a retrospective, cross-sectional study. Drugs Aging. 2011;28(3):195\u2013204.","journal-title":"Drugs Aging"},{"issue":"1","key":"989_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/luts.12285","volume":"12","author":"T Shiota","year":"2020","unstructured":"Shiota T, et al. Cognitive burden and polypharmacy in elderly Japanese patients treated with anticholinergics for an overactive bladder. Low Urin Tract Symptoms. 2020;12(1):54\u201361.","journal-title":"Low Urin Tract Symptoms"},{"issue":"1","key":"989_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/nau.24536","volume":"40","author":"RR Dmochowski","year":"2021","unstructured":"Dmochowski RR, et al. Increased risk of incident dementia following use of anticholinergic agents: a systematic literature review and meta-analysis. Neurourol Urodyn. 2021;40(1):28\u201337.","journal-title":"Neurourol Urodyn"},{"key":"989_CR17","doi-asserted-by":"crossref","unstructured":"Szabo, S.M., et al., Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study. BMJ Open, 2019. 9(5): p. e026391.","DOI":"10.1136\/bmjopen-2018-026391"},{"issue":"9","key":"989_CR18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40266-020-00783-w","volume":"37","author":"S Herschorn","year":"2020","unstructured":"Herschorn S, et al. Safety and tolerability results from the PILLAR study: a phase IV, double-blind, randomized, placebo-controlled study of mirabegron in patients >\/= 65 years with overactive bladder-wet. Drugs Aging. 2020;37(9):665\u201376.","journal-title":"Drugs Aging"},{"issue":"2","key":"989_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.eururo.2019.10.002","volume":"77","author":"A Wagg","year":"2020","unstructured":"Wagg A, et al. Efficacy, safety, and tolerability of mirabegron in patients aged >\/=65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol. 2020;77(2):211\u201320.","journal-title":"Eur Urol"},{"issue":"1","key":"989_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12877-020-1474-7","volume":"20","author":"TL Griebling","year":"2020","unstructured":"Griebling TL, et al. Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatr. 2020;20(1):109.","journal-title":"BMC Geriatr"},{"issue":"1","key":"989_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/bju.15040","volume":"126","author":"B Welk","year":"2020","unstructured":"Welk B, McArthur E. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study. BJU Int. 2020;126(1):183\u201390.","journal-title":"BJU Int"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-022-00989-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-022-00989-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-022-00989-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T15:03:56Z","timestamp":1647875036000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-022-00989-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["989"],"URL":"https:\/\/doi.org\/10.1186\/s12894-022-00989-7","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,21]]},"assertion":[{"value":"31 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were carried out in accordance with the ethical standards of the institutional research committee (University Hospital Medical Information Network Clinical Trials Registry, ID1447) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"There are no potential competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}